Laboratorios Farmaceuticos ROVI SA banner

Laboratorios Farmaceuticos ROVI SA
LSE:0ILL

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
LSE:0ILL
Watchlist
Price: 78.3 EUR -1.45%
Market Cap: €144.7m

EV/FCFF

33.8
Current
13%
Cheaper
vs 3-y average of 38.8

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
33.8
=
Enterprise Value
€4.1B
/
Free Cash Flow to Firm
€119.3m

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
33.8
=
Enterprise Value
€4.1B
/
Free Cash Flow to Firm
€119.3m

Valuation Scenarios

Laboratorios Farmaceuticos ROVI SA is trading below its 3-year average

If EV/FCFF returns to its 3-Year Average (38.8), the stock would be worth €90.01 (15% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-45%
Maximum Upside
+15%
Average Downside
7%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 33.8 €78.3
0%
3-Year Average 38.8 €90.01
+15%
5-Year Average 34.7 €80.54
+3%
Industry Average 34.1 €79.15
+1%
Country Average 18.6 €43.08
-45%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
ES
Laboratorios Farmaceuticos ROVI SA
LSE:0ILL
4B EUR 33.8 28.7
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 140.4 39
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 29.1 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 35.6 28.2
US
Merck & Co Inc
NYSE:MRK
274.6B USD 24.8 15
CH
Novartis AG
SIX:NOVN
216.3B CHF 19.5 20.6
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 43.8 11.6
US
Pfizer Inc
NYSE:PFE
149.3B USD 21.8 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 11.6 16.4

Market Distribution

Lower than 99% of companies in Spain
Percentile
1st
Based on 567 companies
1st percentile
1.7
Low
0 — 13
Typical Range
13 — 28.2
High
28.2 —
Distribution Statistics
Spain
Min 0
30th Percentile 13
Median 18.6
70th Percentile 28.2
Max 1 712.4

Laboratorios Farmaceuticos ROVI SA
Glance View

Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.

0ILL Intrinsic Value
75.24 EUR
Overvaluation 4%
Intrinsic Value
Price €78.3
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett